Form S-3MEF Enliven Therapeutics,
FREE Breaking News Alerts from StreetInsider.com!
- Wall St ends mixed as tech megacap declines outweigh upbeat chip outlook
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- IBM surges on unveiling sub-1nm chip technology breakthrough
- 'Long-term deals significant positive for stock:' Analysts react to Micron results
- Two major earthquakes strike Venezuela, killing at least 32 and injuring hundreds
- Needham Starts NeoVolta (NEOV) at Buy
- Hertz cuts guidance, announces notes and stock offerings, shares sink
- Rockstar Games opens GTA VI pre-orders, priced at $79.99
- Rubio meets Gulf leaders, pledges security amid Iran deal doubts
Goldman Sachs Starts Enliven Therapeutics (ELVN) at Buy
June 16, 2025 5:14 AM EDTGoldman Sachs analyst Salveen Richter initiates coverage on Enliven Therapeutics (NASDAQ: ELVN) with a Buy rating and a price target of $37.00.
The analyst comments "Given continued positive Ph1 data and the announcement of a planned Ph3 initiation in 2026 for tyrosine kinase inhibitor (TKI) ELVN-001 in chronic myeloid leukemia (CML), we assign a Buy rating to ELVN with a $37, 12-month price target, from the previous Early-Stage Biotech designation. ELVN hosted an investor event post the oral presentation at the... More
